Peptide and Compounded Therapy Claims: What Is Established and What Is Not

Checking a peptide therapy claim

Key point: Compounded preparations are not FDA-approved, and the agency does not verify their effectiveness before marketing.

What a good provider should make clear: The clinic names the product, its regulatory status, and the source of any timeline it quotes.

Common mistake: Treating a clinic marketing page as evidence because it is specific about weeks and doses.

Questions to ask: Is this an FDA-approved product, and what is the source for the timeline you just gave me?

What the FDA actually says

The agency's own words: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed."

That sentence covers most peptide preparations sold through wellness clinics. It does not make them illegal, and it does not make them useless.

It does mean the evidence you are being shown is the clinic's, not a regulator's. Ask where it came from.

Why we will not give you a results timeline

A specific number of weeks to a specific effect requires a trial that measured it. For most marketed peptides, no such trial is public.

Publishing a timeline anyway would make this page more citable and less true. The absence is the finding.

If a clinic gives you one, that is not automatically wrong. It is a claim, and claims have sources. Ask for the source.

Where the published price data does exist

The injection procedure itself is priced. Nationally, an injection under the skin or into muscle was allowed at $13.42 against a billed $55.33.

The substance being injected is where the cost sits, and compounded substances have no published price. Ask for it separately.

Questions to ask about any peptide claim

• Is this an FDA-approved product or a compounded preparation?
• Which compounding pharmacy supplies it, and is it registered?
• What is the source for the timeline you have quoted me?
• What would make you stop the treatment?
• What is the cost of the substance, separately from the visit?

Common mistake: reading confident specificity as evidence. Precision and sourcing are different things.

Where these numbers come from, and what they are not

Source: Centers for Medicare & Medicaid Services, Medicare Physician & Other Practitioners — by Geography and Service, calendar year 2024 claims (file released 21 May 2026).

Method: we pull the published rows for each billing code, keep the average submitted charge and the average Medicare allowed amount, and print them unchanged. Nothing is modelled, averaged across codes, or adjusted.

• The submitted charge is what clinicians billed. It is list price. Almost nobody pays it.
• The allowed amount is what Medicare permitted, including the patient's coinsurance. It is a negotiated price.
• These are Medicare fee-for-service claims. The patients skew 65 and older.
• If you are paying cash or using commercial insurance, neither figure is your price. Use the gap between them as a bargaining range, not a quote.
• CMS hides any cell covering fewer than 11 patients, so some states are missing. We print "not published" there rather than guessing.

Common mistake: reading the allowed amount as "the real price" and expecting a clinic to match it. It is what one payer pays one set of clinicians.